AT-4526, A New Quinolone Derivative
Its In Vitro and In Vivo Antibacterial Activity as a Veterinary Medicine
DOI:
https://doi.org/10.21423/aabppro19926617Keywords:
AT-4526, field isolates, antibacterial activities, in vitro, in vivo, bacterial infections, antibiotic resistanceAbstract
Various antibiotics have been used in the treatment of bacterial infections in domestic animals. In recent years, however, outbreaks of infections due to microorganisms resistant to antibiotics are often observed (1, 2, 3). The antibacterial quinolone derivatives does not show cross-resistance with antibiotics (4). AT-4526, 1-cyclopropyl-5,6,8-trifluoro-1 ,4- dihydro-7-(cis-3,5-dimethyl-1-piperazinyl)-4-oxoquinoline-3- carboxylic acid (Fig. 1), is a new quinolone derivative which was synthesized in 1986 (5). This compound, as well as the structurally related enrofloxacin (6), has a high order of activity against a broad spectrum of gram-positive, gram-negative bacteria, and Mycoplasma spp ..
This paper describes the in vitro and in vivo antibacterial activities of AT-4526 against field isolates in domestic animals and the comparison with those of enrofloxacin (ERFX), oxytetracycline (OTC), tylosin (TS), thiamphenicol (TP), kanamycin (KM) and ampicillin (ABPC).